Mounjaro - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The mounjaro market size was valued at USD 23 billion in 2025 and is estimated to grow from USD 29.69 billion in 2026 to reach USD 118.79 billion by 2031, at a CAGR of 31.95% during the forecast period (2026-2031). This report is Segmented by Indication (Type 2 Diabetes, Chronic Weight Management, Obstructive Sleep Apnea), Dosage Form (Pen, Vial), Strength (2. 5 Mg, 5 Mg, and More), Distribution Channel (Hospital Pharmacies, and More), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts Provided are in Value (USD).

Global Mounjaro Market Trends and Insights

Rising Type 2 Diabetes Burden and Earlier Treatment Initiation

The mounjaro market continues to draw strength from the expanding global diabetes population, but the larger commercial shift comes from earlier use of high-efficacy agents in the treatment pathway rather than from prevalence alone. The IDF Diabetes Atlas reported 589 million adults living with diabetes in 2025, with 42.8% of cases still undiagnosed, which leaves a large untreated pool that can move into drug therapy as screening improves. The Mounjaro market is benefiting because treatment practice is moving away from delayed escalation, and dual GIP and GLP-1 therapy is being considered earlier for patients who need glycemic control with parallel weight benefit. SURPASS-PEDS added another layer to this shift by showing efficacy and safety in children and adolescents with Type 2 Diabetes, which opens a new prescribing group that had limited high-efficacy options before 2025. This means the mounjaro market can grow faster than the underlying diagnosed population because more eligible patients are reaching tirzepatide earlier in the care sequence.

Superior Dual GIP and GLP-1 Efficacy Versus Single-Pathway Therapies

The mounjaro market is also being supported by head-to-head clinical evidence that strengthens tirzepatide’s position against competing incretin therapies. SURMOUNT-5 showed that tirzepatide was superior to semaglutide in reducing body weight and waist circumference over 72 weeks, which gave prescribers and payers comparative data that had been missing in this class. The mechanistic case is reinforced by published clinical reviews showing that tirzepatide’s dual receptor activity creates a broader metabolic effect than a single-pathway GLP-1 therapy. A 2025 meta-analysis further supported better weight loss and glycemic outcomes for tirzepatide versus several comparators, which makes formulary preference decisions more defensible for payers. The mounjaro market, therefore, gains not only from patient demand but also from stronger evidence that can shift institutional prescribing patterns in a more durable way.

Premium Monthly Cost and Coverage Restrictions

The mounjaro market still faces a large conversion gap between clinical eligibility and commercial access, especially where obesity treatment is not broadly reimbursed. Lilly’s own self-pay channel is evidence of that gap because the company priced single-dose vials at USD 349 to USD 499 per month to reach patients outside standard coverage pathways. This structure helps the Mounjaro market reach motivated cash-pay patients, but it also shows that mainstream payer support is not yet wide enough to absorb demand at scale through ordinary pharmacy benefit routes. Access conditions are also uneven across indications, because diabetes treatment generally faces a stronger reimbursement base than obesity treatment, which limits how quickly obesity demand can be monetized in community care settings. The mounjaro market can therefore maintain strong patient interest while still losing part of its reachable volume when monthly cost remains the main barrier.

Other drivers and restraints analyzed in the detailed report include:

• Label Expansion Into Obesity and Obstructive Sleep Apnea
• Cross-Condition Use Potential in Cardiometabolic Care Pathways
• Compounded or Off-Label Substitution Pressure in Shortage Cycles

Segment Analysis

Type 2 diabetes held 56.03% of the mounjaro market size in 2025, which kept it as the main revenue base even as newer use cases expanded more quickly. Chronic weight management is projected to grow at 35.84% CAGR through 2031, making it the fastest-moving indication in the mounjaro market as obesity prescribing spreads into broader outpatient settings. The mounjaro market still depends on the diabetes indication for commercial stability because hospital formularies, specialist protocols, and existing treatment pathways were built around glycemic management first. That base gives Lilly a dependable core while newer obesity-linked channels add incremental volume on top of established use.

The second growth layer comes from label broadening and referral diversification. FDA approval for obstructive sleep apnea in adults with obesity created a new channel where pulmonologists and sleep specialists can refer or prescribe tirzepatide, which expands the Mounjaro market beyond the traditional diabetes and obesity clinic base. Pediatric evidence from SURPASS-PEDS also matters because it opens an early-stage opportunity in youth-onset Type 2 Diabetes, where treatment needs are rising and effective options are limited. The American Academy of Sleep Medicine has highlighted that tirzepatide became the first FDA-approved medication for sleep apnea, which reinforces how distinct this pathway is from historical device-led care. Taken together, these developments mean the Mounjaro market is growing through both a well-established base indication and newer referral sources that can keep patient inflow strong over the forecast period.

Single-dose pen accounted for 60.18% of the Mounjaro market size in 2025, reflecting its established fit with hospital, specialty-clinic, and nurse-led injection workflows. That leadership position is tied to provider familiarity and the convenience of a prefilled device in routine diabetes care. The Mounjaro market still leans on the pen format because it supports mainstream prescribing patterns and fits existing administration habits. At the same time, the single-dose vial is forecast to rise at 36.76% CAGR through 2031, which makes it the more disruptive format from a commercial standpoint.

The reason for that disruption is not the container alone, but the access model it enables. Lilly offered approved Zepbound single-dose vials through LillyDirect Self Pay Pharmacy Solutions at USD 349 to USD 499 per month, which created a lower-priced branded route for cash-pay patients and widened access beyond traditional insured dispensing. Lilly then extended that model through Walmart Pharmacy retail pick-up in October 2025, which reduced delivery friction while keeping the direct channel intact. This shift matters because the Mounjaro market can now capture patients who were priced out of conventional branded incretin access but are still willing to self-pay for therapy. The result is that format mix is becoming a commercial strategy issue, not just a device preference issue, within the mounjaro industry.

Complete Report Scope:

• By Diagnosis & Treatment
  • Diagnosis Method
    • Chest X-Ray
    • CT Scan
    • Sputum Culture
    • Blood Tests
    • Pulse Oximetry
  • Treatment Type
    • Antibiotics
    • Oxygen Therapy
    • Hospitalization
    • Supportive Care
• By Pathogen Type
  • Bacterial Pneumonia
  • Viral Pneumonia
  • Fungal Pneumonia
  • Atypical Pneumonia
• By Age Group
  • Infants
  • Children
  • Adults
  • Geriatric Population
• By Risk Factors
  • Chronic Diseases
  • Smoking
  • Alcoholism
  • Weakened Immune System
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.28% of the mounjaro market share in 2025, which kept it as the largest regional contributor. The United States remained the regional core because it had the broadest commercial infrastructure for tirzepatide, the deepest branded obesity demand, and the most advanced direct-to-consumer channel development. Lilly reported USD 22.965 billion in U.S. Mounjaro revenue in FY2025, which showed how much of the global franchise was still concentrated in the domestic base. The region also benefited from the addition of the sleep apnea indication and from stronger availability after earlier supply constraints began to ease.

Asia-Pacific is forecast to grow at 36.04% CAGR through 2031, making it the fastest-expanding regional block in the Mounjaro market. The main reason is scale, because large diabetes populations and broad obesity need to create a much wider long-term treatment pool than most other regions can match. Lilly’s first-quarter 2026 results showed ex-U.S. Mounjaro revenue of USD 4.4 billion, up from USD 1.2 billion in the comparable period of 2025, which signals that international markets are now contributing at a much faster pace. The Mounjaro market in Asia-Pacific also benefits from a mix of mature and emerging demand centers, with established uptake in developed healthcare systems and growing launch momentum in large-volume countries. This makes Asia-Pacific the region where volume expansion is likely to outpace revenue realization most clearly as access broadens and pricing conditions become more varied.

Europe held a meaningful position in the 2025 mounjaro market, supported by established diabetes reimbursement and a large treated population across major Western markets. Growth is steadier in Europe because reimbursement review is generally more measured, especially for obesity use, even when clinical interest is strong. Lilly’s November 2025 decision to build a USD 3 billion oral medicine manufacturing facility in the Netherlands showed that the company views Europe as strategically important both for supply and for future platform expansion. Middle East and Africa, and South America remain earlier-stage opportunities in the Mounjaro market, with adoption still building from a smaller base. Their role in the forecast period is less about immediate share leadership and more about adding new pockets of demand as regulatory access and commercial infrastructure continue to improve.

List of Companies Covered in this Report:

• Abbott Laboratories
• Abbvie
• APTARION Biotech AG
• AstraZeneca
• Basilea Pharmaceutica Ltd.
• Beckton Dickinson
• bioMérieux S.A.
• Eagle Pharmaceuticals, Inc.
• GlaxoSmithKline
• GlaxoSmithKline
• Hologic
• Melinta Therapeutics LLC
• Merck
• Nabriva Therapeutics plc
• Novartis
• Paratek Pharmaceuticals
• Pfizer
• QuidelOrtho
• Roche
• Sanofi
• Shionogi and Co., Ltd.
• Takeda Pharmaceuticals
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support